셀트리온, 유방암 치료제 ‘허쥬마SC’ 제형 추가 신청…신성장동력 확보

Celltrion's application for Herzuma SC marks a strategic expansion into the SC biosimilar market, leveraging its proprietary Hyaluronidase platform to enhance patient convenience and hospital efficiency. This move not only secures early market dominance in the Trastuzumab segment but also positions the company to venture into formulation-based CDMO services, diversifying its long-term growth engines.